Hengrui Pharma(SH:600276) Zheng Quan Shi Bao Wang·2025-09-05 02:46Group 1 - On September 5, 2023, Heng Rui Medicine announced an exclusive licensing agreement with Braveheart Bio for its self-developed cardiac myosin small molecule inhibitor HRS-1893, granting Braveheart Bio rights to develop, produce, and commercialize HRS-1893 globally, excluding Greater China [1] - Braveheart Bio will pay a total of $75 million to Heng Rui Medicine, which includes a $65 million upfront payment (comprising $32.5 million in cash and $32.5 million in Braveheart Bio equity) and a $10 million milestone payment upon completion of technology transfer [1] - Heng Rui Medicine could receive up to $1.013 billion in milestone payments related to clinical development and sales, along with corresponding sales royalties [1] Group 2 - Braveheart Bio was established in 2024 in Delaware, USA, with major investors including Forbion Capital and OrbiMed, both of which are influential in the life sciences investment sector [2] - The partnership with top-tier life sciences investment institutions highlights Heng Rui Medicine's international competitiveness and accelerates the global development of innovative therapies in the cardiovascular field [2] - HRS-1893 is a significant innovation in Heng Rui Medicine's cardiovascular portfolio, currently in Phase III clinical trials, with over 10 innovative products in clinical research stages targeting cardiovascular diseases [3] Group 3 - Heng Rui Medicine emphasizes a dual approach of independent research and open collaboration to enhance its global innovation footprint, actively exploring partnerships with multinational pharmaceutical companies, innovative startups, and leading regional pharmaceutical firms [3]